BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283-1294. [PMID: 27451390 DOI: 10.1016/s1470-2045(16)30167-x] [Cited by in Crossref: 664] [Cited by in F6Publishing: 709] [Article Influence: 94.9] [Reference Citation Analysis]
Number Citing Articles
1 Gaudio F, Loseto G, Bozzoli V, Scalzulli PR, Mazzone AM, Tonialini L, Fesce V, Quintana G, De Santis G, Masciopinto P, Arcuti E, Clemente F, Scardino S, Tarantini G, Pastore D, Melillo L, Pavone V, Maggi A, Carella AM, Di Renzo N, Guarini A, Musto P. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma. Ann Hematol 2023. [PMID: 36645458 DOI: 10.1007/s00277-023-05100-0] [Reference Citation Analysis]
2 Barrett A, Collins GP. Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1017787] [Reference Citation Analysis]
3 Soldi LR, Silva VLC, Rabelo DH, Uehara IA, Silva MJB. Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. J Cancer Res Clin Oncol 2023. [PMID: 36633682 DOI: 10.1007/s00432-023-04575-8] [Reference Citation Analysis]
4 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
5 McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol 2023;9:102-11. [PMID: 36480191 DOI: 10.1001/jamaoncol.2022.5409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee B, Rui-jeat F, Soon-keng C. Immunotherapy for Hematological Cancers. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_226-1] [Reference Citation Analysis]
7 Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. JCO 2022. [DOI: 10.1200/jco.22.02355] [Reference Citation Analysis]
8 Kambhampati S, Herrera AF. Incorporating novel agents into frontline treatment of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2022;2022:706-16. [PMID: 36485085 DOI: 10.1182/hematology.2022000363] [Reference Citation Analysis]
9 Sedano R, Cabrera D, Jiménez A, Ma C, Jairath V, Arrese M, Arab JP. Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. Am J Gastroenterol 2022;117:1917-32. [PMID: 36455219 DOI: 10.14309/ajg.0000000000001983] [Reference Citation Analysis]
10 Griguolo G, Zorzi M, Pirosa M, Treglia G, Bertoni F, Kuruvilla J, Zucca E, Stathis A. A systematic review of contemporary phase I trials in patients with lymphoma. Critical Reviews in Oncology/Hematology 2022;180:103860. [DOI: 10.1016/j.critrevonc.2022.103860] [Reference Citation Analysis]
11 Stamatoullas A, Ghesquières H, Feugier P, André M, Le Bras F, Gac AC, Borel C, Gastinne T, Quittet P, Morschhauser F, Ribrag V, Guidez S, Nicolas-Virelizier E, Berriolo-Riedinger A, Vander Borght T, Edeline V, Brice P. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. Leuk Lymphoma 2022;63:3063-71. [PMID: 35975738 DOI: 10.1080/10428194.2022.2107204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bajpai J, Philip DSJ. “A.B.C.” of Immunotherapy in Hematological Malignancies…Promise and Perils. Indian J Med Paediatr Oncol 2022. [DOI: 10.1055/s-0042-1749321] [Reference Citation Analysis]
13 De Re V, Repetto O, Mussolin L, Brisotto G, Elia C, Lopci E, d'Amore ESG, Burnelli R, Mascarin M. Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma. Front Cell Dev Biol 2022;10:965803. [PMID: 36506094 DOI: 10.3389/fcell.2022.965803] [Reference Citation Analysis]
14 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
15 Hazane Leroyer E, Ziegler C, Moulin C, Campidelli A, Jacquet C, Rubio MT, Feugier P, Pagliuca S. Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma. JCM 2022;11:6574. [DOI: 10.3390/jcm11216574] [Reference Citation Analysis]
16 Hanada K, Tsunoda S, Nomura M, Fujimura S, Yutaka Y, Nishigori T, Hisamori S, Maekewa H, Hoshino N, Itami A, Tanaka E, Obama K. A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. surg case rep 2022;8:206. [DOI: 10.1186/s40792-022-01561-z] [Reference Citation Analysis]
17 Huang J, Huang J. Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. Immune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title] 2022. [DOI: 10.5772/intechopen.107435] [Reference Citation Analysis]
18 Iscaro A, H.n. Howard F, Yang Z, Jenkins F, Muthana M. Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. Liposomes - Recent Advances, New Perspectives and Applications [Working Title] 2022. [DOI: 10.5772/intechopen.108282] [Reference Citation Analysis]
19 Wang Y, Wang B, Xiang L, Deng J, Xu B, He P, Pu W, Wang H, Fan Y, Chen H. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. Front Immunol 2022;13:1016647. [DOI: 10.3389/fimmu.2022.1016647] [Reference Citation Analysis]
20 Kosydar S, Ansell SM. Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2131422] [Reference Citation Analysis]
21 Li Z, Duan Y, Ke Q, Wang M, Cen H, Zhu X. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. Front Genet 2022;13:1000460. [DOI: 10.3389/fgene.2022.1000460] [Reference Citation Analysis]
22 Moskowitz AJ. EXABS-208-HL Sequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2022;22 Suppl 2:S101-3. [PMID: 36163704 DOI: 10.1016/S2152-2650(22)00682-6] [Reference Citation Analysis]
23 Ferdinandus J, Oertel M, Eichenauer DA, Meissner J, Engert A, Borchmann P. Das Hodgkin-Lymphom in fortgeschrittenen Stadien. Onkologie 2022;28:889-900. [DOI: 10.1007/s00761-022-01186-9] [Reference Citation Analysis]
24 Bröckelmann PJ, von Tresckow B, Engert A. Neue Ansätze zur Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms. Onkologie 2022;28:901-907. [DOI: 10.1007/s00761-022-01172-1] [Reference Citation Analysis]
25 Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, Singla DK, Hooper DC, Lu B. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol 2022;12:940127. [DOI: 10.3389/fonc.2022.940127] [Reference Citation Analysis]
26 Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol 2022;13:964442. [DOI: 10.3389/fimmu.2022.964442] [Reference Citation Analysis]
27 Zhao X, Ma Y, Bian H, Liu Z. CD20 expression is closely associated with Epstein–Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma. Front Oncol 2022;12:993768. [DOI: 10.3389/fonc.2022.993768] [Reference Citation Analysis]
28 Couto ME, Vaz CP, Branca R, Leite L, Brás G, Roncon S, Campos A. Allogeneic stem cell transplant in relapsed/ refractory Hodgkin lymphoma: A 21 years’ experience. Porto Biomedical Journal 2022;7:e173. [DOI: 10.1097/j.pbj.0000000000000173] [Reference Citation Analysis]
29 Odeny TA, Lurain K, Strauss J, Fling SP, Sharon E, Wright A, Martinez-picado J, Moran T, Gulley JL, Gonzalez-cao M, Uldrick TS, Yarchoan R, Ramaswami R. Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. J Immunother Cancer 2022;10:e005128. [DOI: 10.1136/jitc-2022-005128] [Reference Citation Analysis]
30 Samaneva NY, Lysenko IB, Nikolaeva NV, Kapuza EA, Kamaeva IA, Gaysultanova YS, Tishina AV, Pushkareva TF. EVOLUTION OF DRUG THERAPY FOR CLASSICAL HODGKIN LYMPHOMA. jour 2022;3:41-47. [DOI: 10.37748/2686-9039-2022-3-3-5] [Reference Citation Analysis]
31 Wen Q, Ge J, Lei Y, Zhang Y, Kong X, Wang W, Hou H, Wang Z, Qian S, Ding M, Dong M, Zhu L, Zhang M, Zhang X, Chen Q. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04321-6] [Reference Citation Analysis]
32 Cui C, Deng L, Wang W, Ren X, Wang Y, Cui W. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. Front Oncol 2022;12:941079. [DOI: 10.3389/fonc.2022.941079] [Reference Citation Analysis]
33 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
34 Takiar R, Karimi Y. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose? Cancers 2022;14:3526. [DOI: 10.3390/cancers14143526] [Reference Citation Analysis]
35 Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Liu L, Yu G, Hu Y, Zhao Z, Liu L, Xue H, Luo J, He B, Jin X, Zhao M, Li B, Xia Y, Zhu J. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Front Oncol 2022;12:925236. [DOI: 10.3389/fonc.2022.925236] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Raut M, Singh G, Hiscock I, Sharma S, Pilkhwal N. A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma. Expert Rev Hematol 2022;:1-11. [PMID: 35794714 DOI: 10.1080/17474086.2022.2080050] [Reference Citation Analysis]
37 Xie W, Medeiros LJ, Li S, Tang G, Fan G, Xu J. PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. Biomedicines 2022;10:1587. [DOI: 10.3390/biomedicines10071587] [Reference Citation Analysis]
38 Chohan KL, Ansell SM. The broader prospects for bispecifics in Hodgkin lymphoma. Leukemia & Lymphoma 2022;63:1777-1779. [DOI: 10.1080/10428194.2022.2107205] [Reference Citation Analysis]
39 Druce I, Tawagi K, Shaw JLV, Ibrahim A, Lochnan H, Ong M. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists. Current Oncology 2022;29:4665-4677. [DOI: 10.3390/curroncol29070370] [Reference Citation Analysis]
40 Amzai G, Karanfilski O. Milestones in Hematology and Oncology: From Fatal to Curable Disease. PRILOZI 2022;43:145-157. [DOI: 10.2478/prilozi-2022-0027] [Reference Citation Analysis]
41 Yang L, Department of Geriatrics, Guangzhou First People’s Hospital, Guangzhou 510000, China, Xu X, Department of Geriatrics, Guangzhou First People’s Hospital, Guangzhou 510000, China. Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas. APT 2022;4:38-45. [DOI: 10.31491/apt.2022.06.084] [Reference Citation Analysis]
42 Nakhoda S, Rizwan F, Vistarop A, Nejati R. Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma. Cancers (Basel) 2022;14:2936. [PMID: 35740598 DOI: 10.3390/cancers14122936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Lv M, Liu Y, Liu W, Xing Y, Zhang S. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. Front Immunol 2022;13:921894. [DOI: 10.3389/fimmu.2022.921894] [Reference Citation Analysis]
44 Iikura Y, Aoyama T, Hiraide M, Wakatsuki T, Nakayama I, Ogura M, Ooki A, Takahari D, Chin K, Yamaguchi K, Hama T. Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. Health Sci Rep 2022;5:e673. [PMID: 35662976 DOI: 10.1002/hsr2.673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A, Han W, Qian W. Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications. [DOI: 10.1002/cac2.12313] [Reference Citation Analysis]
46 Roelofsen L, Kaptein P, Thommen D. Multimodal predictors for precision immunotherapy. Immuno-Oncology and Technology 2022;14:100071. [DOI: 10.1016/j.iotech.2022.100071] [Reference Citation Analysis]
47 Waheed A, Rodday AM, Kumar AJ, Miller KB, Parsons SK. Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data. JCO Clin Cancer Inform 2022;6:e2100135. [PMID: 35584337 DOI: 10.1200/CCI.21.00135] [Reference Citation Analysis]
48 Beynarovich A, Lepik K, Mikhailova N, Borzenkova E, Volkov N, Moiseev I, Zalyalov Y, Kondakova E, Kozlov A, Stelmakh L, Pirogova O, Zubarovskaya L, Kulagin A, Afanasyev B. Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma. Int J Hematol 2022. [PMID: 35511399 DOI: 10.1007/s12185-022-03355-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Yhim HY, Eshet Y, Metser U, Lajkosz K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Xu W, Rodin D, Hodgson D, Tsang R, Crump M, Kuruvilla J, Kridel R. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol 2022;97:583-91. [PMID: 35170780 DOI: 10.1002/ajh.26500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Fattizzo B, Rampi N, Barcellini W. Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. Pharmaceuticals 2022;15:557. [DOI: 10.3390/ph15050557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Takahara T, Ishikawa E, Suzuki Y, Kogure Y, Sato A, Kataoka K, Nakamura S. PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3'-UTR structural variations. J Clin Exp Hematop 2022. [PMID: 35474033 DOI: 10.3960/jslrt.21028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Blanco M, Collazo-Lorduy A, Yanguas-Casás N, Calvo V, Provencio M. Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. Cancers (Basel) 2022;14:2158. [PMID: 35565286 DOI: 10.3390/cancers14092158] [Reference Citation Analysis]
53 Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, Cheikh J, Briones J, Gülbas Z, Hamladji RM, Elverdi T, Blaise D, Martínez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia 2022. [PMID: 35414657 DOI: 10.1038/s41375-022-01563-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Pathak N, Pramanik R, Bakhshi S, Kumar A, Sharma MC, Shamim SA, Kumar S, Thulkar S, Sharma A. Modified Protocol of Nivolumab in Relapsed/Refractory Hodgkin Lymphoma: A Brief Communication of Real World Data. J Immunother 2022. [PMID: 35404324 DOI: 10.1097/CJI.0000000000000411] [Reference Citation Analysis]
55 Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol 2022;13:862084. [DOI: 10.3389/fimmu.2022.862084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Cook MR, Dunleavy K. Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01250-y] [Reference Citation Analysis]
57 Manji F, Laister RC, Kuruvilla J. An evaluation of pembrolizumab for classical Hodgkin lymphoma. Expert Rev Hematol 2022. [PMID: 35389317 DOI: 10.1080/17474086.2022.2061947] [Reference Citation Analysis]
58 Kyriazoglou A, Beuselinck B. Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research. Acta Clin Belg 2022;77:406-9. [PMID: 33308043 DOI: 10.1080/17843286.2020.1853886] [Reference Citation Analysis]
59 Samara Y, Mei M. Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies. Cancers (Basel) 2022;14:1738. [PMID: 35406509 DOI: 10.3390/cancers14071738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Ye Q, Lin Y, Li R, Wang H, Dong C. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Semin Cancer Biol 2022:S1044-579X(22)00072-4. [PMID: 35339668 DOI: 10.1016/j.semcancer.2022.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Gholiha AR, Hollander P, Löf L, Glimelius I, Hedstrom G, Molin D, Hjalgrim H, Smedby KE, Hashemi J, Amini RM, Enblad G. Checkpoint CD47 expression in classical Hodgkin lymphoma. Br J Haematol 2022. [PMID: 35301709 DOI: 10.1111/bjh.18137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Smith CM, Friedman DL. Advances in Hodgkin Lymphoma: Including the Patient's Voice. Front Oncol 2022;12:855725. [PMID: 35280764 DOI: 10.3389/fonc.2022.855725] [Reference Citation Analysis]
64 Roshandel E, Tavakoli F, Parkhideh S, Akhlaghi SS, Ardakani MT, Soleimani M. Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors. Health Sci Rep 2022;5:e536. [PMID: 35284650 DOI: 10.1002/hsr2.536] [Reference Citation Analysis]
65 Naccache R, Belkouchi Y, Lawrance L, Benatsou B, Hadchiti J, Cournede P, Ammari S, Talbot H, Lassau N. Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. Cancers 2022;14:1337. [DOI: 10.3390/cancers14051337] [Reference Citation Analysis]
66 Biggi AFB, Elgui de Oliveira D. The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers. Biomolecules 2022;12:397. [DOI: 10.3390/biom12030397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Zheng H, Guo B, Qiu X, Xia Y, Qu Y, Cheng L, Meng F, Zhong Z. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy. Bioactive Materials 2022. [DOI: 10.1016/j.bioactmat.2022.02.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
68 Khan M, Hagemeister F, Wang M, Ahmed S. A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100949] [Reference Citation Analysis]
69 Lin AY, Schnitter JM, Gordon LI. Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma. ITT 2022;Volume 11:1-10. [DOI: 10.2147/itt.s284988] [Reference Citation Analysis]
70 Chohan K, Ansell SM. Current salvage therapies in Hodgkin lymphoma. Leuk Lymphoma 2022;:1-14. [PMID: 35037568 DOI: 10.1080/10428194.2021.2024819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Onishi A, Fuji S, Kitano S, Maeshima AM, Tajima K, Yamaguchi J, Kawashima I, Kawajiri A, Takemura T, Ito A, Tanaka T, Okinaka K, Inamoto Y, Kurosawa S, Kim SW, Munakata W, Maruyama D, Tobinai K, Fukuda T. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. Ann Hematol 2022. [PMID: 35032188 DOI: 10.1007/s00277-022-04760-8] [Reference Citation Analysis]
73 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
74 Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess 2021;25:1-228. [PMID: 34990339 DOI: 10.3310/hta25760] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 Vassilakopoulos TP, Liaskas A, Piperidou A, Ioakim M, Prassopoulos V. The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications. Artificial Intelligence in PET/CT Oncologic Imaging 2022. [DOI: 10.1007/978-3-031-10090-1_14] [Reference Citation Analysis]
76 Popovic LS, Brko GM, Popovic M. Immunotherapy of Lymphoma. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_229-1] [Reference Citation Analysis]
77 Keshavarz-fathi M, Keshavarz-fathi M, Rezaei N. Cancer Immunology. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00083-5] [Reference Citation Analysis]
78 Wudhikarn K, Ansell SM. Principles of Checkpoint Inhibition in Malignant Lymphoma. Cancer Immunotherapy 2022. [DOI: 10.1007/13905_2022_18] [Reference Citation Analysis]
79 Zhang XY, Collins GP. Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway. Curr Oncol Rep 2022;24:1477-88. [PMID: 35696020 DOI: 10.1007/s11912-022-01292-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Gao F, Tian L, Shi H, Zheng P, Wang J, Dong F, Hu K, Ke X. Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. Front Genet 2021;12:677650. [PMID: 34925435 DOI: 10.3389/fgene.2021.677650] [Reference Citation Analysis]
81 Fathi M, Vakili K, Jazi K, Sadeghi MA, Hajiesmaeili M, Mohamadkhani A, Rezaei-Tavirani M, Tavasol A. Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. Tumori 2021;:3008916211063939. [PMID: 34918602 DOI: 10.1177/03008916211063939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Carty SA. Immunology 101: fundamental immunology for the practicing hematologist. Hematology 2021;2021:281-286. [DOI: 10.1182/hematology.2021000260] [Reference Citation Analysis]
83 Perincheri S. Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies. Front Oncol 2021;11:719140. [DOI: 10.3389/fonc.2021.719140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Velasco R, Domingo-Domenech E, Sureda A. Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers (Basel) 2021;13:6125. [PMID: 34885234 DOI: 10.3390/cancers13236125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Sasse S, Momotow J, Engert A. Checkpoint-Inhibitoren bei Hodgkin-Lymphom. best practice onkologie 2021;16:558-566. [DOI: 10.1007/s11654-021-00348-2] [Reference Citation Analysis]
86 Hu F, Zhai Y, Yuan L, Liang J, Xu J, Guo X, Zhou X, Lin Z, Sun J, Ye X, He J. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database. Cancer Med 2021;10:8754-62. [PMID: 34845857 DOI: 10.1002/cam4.4343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Modi D, Potugari B, Uberti J. Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers (Basel) 2021;13:5827. [PMID: 34830980 DOI: 10.3390/cancers13225827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
88 Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Schmitz C, Borchmann S, Bröckelmann PJ, Heger JM, Fuchs M, Engert A, Borchmann P, von Tresckow B. Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). Br J Haematol 2021. [PMID: 34775591 DOI: 10.1111/bjh.17878] [Reference Citation Analysis]
89 Alkhilaiwi F. Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. Front Oncol 2021;11:761986. [PMID: 34737964 DOI: 10.3389/fonc.2021.761986] [Reference Citation Analysis]
90 Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, Khoshavi N, Karimi N, Shirinisaz A, Abedi F, Rad MR, Sharifi P. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol 2021;232:108873. [PMID: 34688855 DOI: 10.1016/j.clim.2021.108873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
91 Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers (Basel) 2021;13:5277. [PMID: 34771441 DOI: 10.3390/cancers13215277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Fakhri B, Ai W. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol 2021;12:20406207211048959. [PMID: 34659697 DOI: 10.1177/20406207211048959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
93 Aoki T, Chong LC, Takata K, Milne K, Marshall A, Chavez EA, Miyata-Takata T, Ben-Neriah S, Unrau D, Telenius A, Boyle M, Weng AP, Savage KJ, Scott DW, Farinha P, Shah SP, Nelson BH, Steidl C. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proc Natl Acad Sci U S A 2021;118:e2105822118. [PMID: 34615710 DOI: 10.1073/pnas.2105822118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Opinto G, Agostinelli C, Ciavarella S, Guarini A, Maiorano E, Ingravallo G. Hodgkin Lymphoma: A Special Microenvironment. J Clin Med 2021;10:4665. [PMID: 34682791 DOI: 10.3390/jcm10204665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Bröckelmann PJ, Müller H, Gillessen S, Yang X, Koeppel L, Pilz V, Marinello P, Kaskel P, Raut M, Fuchs M, Borchmann P, Engert A, von Tresckow B. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia 2021. [PMID: 34628472 DOI: 10.1038/s41375-021-01442-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Zhang YC, Wang JN, Ma SY, Cai J, Su N, Huang HQ, Li ZM, Xia ZJ, Huang H, Liu PP, Xia Y, Cai QQ. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma. Br J Haematol 2021. [PMID: 34618912 DOI: 10.1111/bjh.17849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
97 Stefania Infante M, Fernández-Cruz A, Núñez L, Carpio C, Jiménez-Ubieto A, López-Jiménez J, Vásquez L, Del Campo R, Romero S, Alonso C, Morillo D, Prat M, Luis Plana J, Villafuerte P, Bastidas G, Bocanegra A, Serna Á, De Nicolás R, Marquet J, Mas-Ochoa C, Cordoba R, García-Suárez J, Comai A, Martín X, Bastos-Oreiro M, Seri C, Navarro-Matilla B, López-Guillermo A, Martínez-López J, Ángel Hernández-Rivas J, Ruiz-Camps I, Grande C; Grupo Español de Linfomas y Trasplante Autólogo de Medula Ósea (GELTAMO). Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Med 2021;10:7629-40. [PMID: 34558211 DOI: 10.1002/cam4.4293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
98 Patel J, Garg A, Patel K, Shah K, Shah S, Yadav R, Anand A, Panchal H, Patel A, Parikh S, Shah S. Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01490-1] [Reference Citation Analysis]
99 Ikegawa S, Matsuoka KI. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Front Immunol 2021;12:713358. [PMID: 34526990 DOI: 10.3389/fimmu.2021.713358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Herrera AF, Burton C, Radford J, Miall F, Townsend W, Santoro A, Zinzani PL, Lewis D, Fowst C, Brar S, Huang B, Thall A, Collins GP. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv 2021;5:3387-96. [PMID: 34477818 DOI: 10.1182/bloodadvances.2021004511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
102 Guerini AE, Filippi AR, Tucci A, Simontacchi G, Re A, Guaineri A, Morelli V, Borghetti P, Triggiani L, Pegurri L, Pedretti S, Volpi G, Spiazzi L, Magrini SM, Buglione M. 'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)02035-8. [PMID: 34728169 DOI: 10.1016/j.clml.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Wullenkord R, Berning P, Niemann AL, Wethmar K, Bergmann S, Lutz M, Schliemann C, Mesters R, Keßler T, Schmitz N, Berdel WE, Lenz G, Stelljes M. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol 2021;100:2733-44. [PMID: 34477953 DOI: 10.1007/s00277-021-04650-5] [Reference Citation Analysis]
104 Breschi GL, Demma F, Morelli P, De Francesco M. Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy. abtpn 2021;8:81-7. [DOI: 10.33393/ao.2021.2263] [Reference Citation Analysis]
105 Müller F. Neue antikörperbasierte Therapien in der Hämatologie. best practice onkologie 2021;16:364-378. [DOI: 10.1007/s11654-021-00331-x] [Reference Citation Analysis]
106 Cho J, Yoon SE, Kim SJ, Ko YH, Kim WS. Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer 2021;21:972. [PMID: 34461835 DOI: 10.1186/s12885-021-08695-7] [Reference Citation Analysis]
107 Rossi C, Casasnovas RO. PD-1 inhibitors in patients with Hodgkin lymphoma. Eur J Cancer 2021:S0959-8049(21)00478-0. [PMID: 34456113 DOI: 10.1016/j.ejca.2021.06.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Lyadova MA, Lyadov VK. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. J Mod Onco 2021;23:319-326. [DOI: 10.26442/18151434.2021.2.200502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Gehrcken L, Sauerer T, Schaft N, Dörrie J. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. Int J Mol Sci 2021;22:8679. [PMID: 34445385 DOI: 10.3390/ijms22168679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J Pers Med 2021;11:749. [PMID: 34442393 DOI: 10.3390/jpm11080749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
111 Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048 [PMID: 34368325 DOI: 10.12998/wjcc.v9.i21.6041] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Farttoosi MA, El Cheikh J. Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story. Bone Marrow Transplant 2021. [PMID: 34304253 DOI: 10.1038/s41409-021-01396-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Akimoto T, Shitara K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 2020;4:e000775. [PMID: 32719002 DOI: 10.1136/esmoopen-2020-000775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
114 Kusumoto S. VI. Pathogenesis, Diagnosis and Treatment in Adult Classic Hodgkin Lymphoma. J Jpn Soc Intern Med 2021;110:1426-1433. [DOI: 10.2169/naika.110.1426] [Reference Citation Analysis]
115 Tarekegn K, Colon Ramos A, Singh B, Sequeira Gross HG, Gupta S. Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma. World J Oncol 2021;12:81-4. [PMID: 34349851 DOI: 10.14740/wjon1388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Zou W, Lu J, Hao Y. Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. J Inflamm Res 2021;14:3077-88. [PMID: 34267536 DOI: 10.2147/JIR.S311616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
118 Que Y, Wang J, Zhu J, Li N, Huang J, Lu S, Sun F, Zhang L, Zhen Z, Zhang L, Cai R, Guo H, Sun X, Zhang Y. Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. Front Immunol 2021;12:647733. [PMID: 34295326 DOI: 10.3389/fimmu.2021.647733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Gomez F, Mosior M, Mcmichael J, Skidmore ZL, Duncavage EJ, Miller CA, Abel HJ, Li Y, Krysiak K, Russler-germain DA, Watkins MP, Ramirez C, Schmidt A, Rodrigues FM, Trani L, Khanna A, Wagner JA, Fulton RS, Fronick C, O’laughlin M, Schappe T, Cashen A, Mehta-shah N, Kahl BS, Walker J, Bartlett NL, Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma.. [DOI: 10.1101/2021.06.25.21258374] [Reference Citation Analysis]
120 Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open 2020;5:e000611. [PMID: 31958292 DOI: 10.1136/esmoopen-2019-000611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
121 Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M. Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. J Cancer Res Clin Oncol 2021. [PMID: 34176014 DOI: 10.1007/s00432-021-03702-7] [Reference Citation Analysis]
122 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 45.5] [Reference Citation Analysis]
123 Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med 2021;19:238. [PMID: 34078406 DOI: 10.1186/s12967-021-02895-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, Mir O. Targeting the VEGF Pathway in Osteosarcoma. Cells 2021;10:1240. [PMID: 34069999 DOI: 10.3390/cells10051240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
125 De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, Montes de Oca C, Duléry R, Bouabdallah R, Granata A, Devillier R, Mariotti J, Sarina B, Harbi S, Maisano V, Furst S, Pagliardini T, Weiller PJ, Lemarie C, Calmels B, Chabannon C, Santoro A, Mohty M, Blaise D, Castagna L. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv 2020;4:1242-9. [PMID: 32227210 DOI: 10.1182/bloodadvances.2019001336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
126 Cassaday RD, Garcia KA, Fromm JR, Percival MM, Turtle CJ, Nghiem PT, Stevenson PA, Estey EH. Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Adv 2020;4:3239-45. [PMID: 32692850 DOI: 10.1182/bloodadvances.2020002403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
127 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
128 Tobin JWD, Bednarska K, Campbell A, Keane C. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells 2021;10:1152. [PMID: 34068762 DOI: 10.3390/cells10051152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Olivares-Hernández A, Figuero-Pérez L, Terán-Brage E, López-Gutiérrez Á, Velasco ÁT, Sarmiento RG, Cruz-Hernández JJ, Miramontes-González JP. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. J Clin Med 2021;10:1919. [PMID: 33925214 DOI: 10.3390/jcm10091919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
130 Pro B, Shustov A. Emerging Immunotherapy Approaches in Peripheral T‐cell Lymphomas. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch24] [Reference Citation Analysis]
131 Terao T, Yuda J, Yamauchi N, Guo YM, Shimada K, Sugano M, Ishii G, Minami Y. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission. Mol Clin Oncol 2021;14:125. [PMID: 33936598 DOI: 10.3892/mco.2021.2287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2021;68 Suppl 2:e28562. [PMID: 33818890 DOI: 10.1002/pbc.28562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, Shi F, Brock M, Liu M, Mei Q, Liu J, Nie J, Han W. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer 2021;9:e002347. [PMID: 33820822 DOI: 10.1136/jitc-2021-002347] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
134 Zhang W, Qiu Y, Xie X, Fu Y, Wang L, Cai Z. B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? Front Oncol 2021;11:647526. [PMID: 33869045 DOI: 10.3389/fonc.2021.647526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Li F, Chen Y, Pang M, Yang P, Jing H. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy. Clin Exp Immunol 2021;205:1-11. [PMID: 33675535 DOI: 10.1111/cei.13592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
136 Jimbu L, Mesaros O, Popescu C, Neaga A, Berceanu I, Dima D, Gaman M, Zdrenghea M. Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia? Pharmaceuticals (Basel) 2021;14:288. [PMID: 33804850 DOI: 10.3390/ph14040288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
137 Csizmar CM, Ansell SM. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. Int J Mol Sci 2021;22:3302. [PMID: 33804869 DOI: 10.3390/ijms22073302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
138 Bobillo S, Nieto JC, Barba P. Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. Bone Marrow Transplant 2021;56:1784-93. [PMID: 33742152 DOI: 10.1038/s41409-021-01268-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Ferrari C, Maggialetti N, Masi T, Nappi AG, Santo G, Niccoli Asabella A, Rubini G. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. J Pers Med 2021;11:217. [PMID: 33803667 DOI: 10.3390/jpm11030217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
140 Chervontseva AM, Verniuk MA, Gushchina EE, Cherkashina IV, Fedenko AA. EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA. Sib onkol ž 2021;20:155-161. [DOI: 10.21294/1814-4861-2021-20-1-155-161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Antel K, Chetty D, Oosthuizen J, Mohamed Z, Van der Vyver L, Verburgh E. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. Pathology 2021;53:628-34. [PMID: 33558066 DOI: 10.1016/j.pathol.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Chen H, Zhou Y, Han X, Shi Y. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review. Lancet Reg Health West Pac 2021;8:100097. [PMID: 34327425 DOI: 10.1016/j.lanwpc.2021.100097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Xiong Y, Zhou H, Du X, Wang X, Peng B. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine 2020;54:102731. [PMID: 32304999 DOI: 10.1016/j.ebiom.2020.102731] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
144 Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol 2020;6:872-80. [PMID: 32352505 DOI: 10.1001/jamaoncol.2020.0750] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 33.0] [Reference Citation Analysis]
145 Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M. Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. Mol Imaging Biol 2020;22:47-65. [PMID: 31049831 DOI: 10.1007/s11307-019-01361-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Jeong AR, Ball ED, Goodman AM. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clin Med Insights Oncol 2020;14:1179554920976366. [PMID: 33447123 DOI: 10.1177/1179554920976366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol 2021;39:514-24. [PMID: 33434061 DOI: 10.1200/JCO.20.01709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
148 Shi Y, Tomczak K, Li J, Ochieng JK, Lee Y, Haymaker C. Next-Generation Immunotherapies to Improve Anticancer Immunity. Front Pharmacol 2020;11:566401. [PMID: 33505304 DOI: 10.3389/fphar.2020.566401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
149 Crump M. Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma? J Clin Oncol 2021;39:97-9. [PMID: 33275485 DOI: 10.1200/JCO.20.02905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Armengol M, Santos JC, Fernández-Serrano M, Profitós-Pelejà N, Ribeiro ML, Roué G. Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers (Basel) 2021;13:E214. [PMID: 33430146 DOI: 10.3390/cancers13020214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
151 Wu Z, Nicoll M, Ingham RJ. AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL. Exp Hematol Oncol 2021;10:4. [PMID: 33413671 DOI: 10.1186/s40164-020-00197-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
152 Othman T, Herrera A, Mei M. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Curr Hematol Malig Rep 2021;16:1-7. [PMID: 33409966 DOI: 10.1007/s11899-020-00603-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Ascierto PA, Butterfield LH, Campbell K, Daniele B, Dougan M, Emens LA, Formenti S, Janku F, Khleif SN, Kirchhoff T, Morabito A, Najjar Y, Nathan P, Odunsi K, Patnaik A, Paulos CM, Reinfeld BI, Skinner HD, Timmerman J, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). J Transl Med 2021;19:13. [PMID: 33407605 DOI: 10.1186/s12967-020-02627-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Rhiel L, Becker S. Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences 2021. [DOI: 10.1007/978-3-030-54630-4_6] [Reference Citation Analysis]
155 Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest 2020;130:1576-85. [PMID: 32039913 DOI: 10.1172/JCI129206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
156 Penter L, Wu CJ. Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. J Clin Invest 2020;130:1595-607. [PMID: 31985488 DOI: 10.1172/JCI129209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
157 Augé H, Notarantonio AB, Morizot R, Quinquenel A, Fornecker LM, Hergalant S, Feugier P, Broséus J. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. Front Immunol 2020;11:594841. [PMID: 33381116 DOI: 10.3389/fimmu.2020.594841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
158 Laliberté F, Raut M, Yang X, Germain G, Nahar A, Desai KD, MacKnight SD, Sen SS, Duh MS. Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA. Target Oncol 2021;16:85-94. [PMID: 33284424 DOI: 10.1007/s11523-020-00778-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Hodkinson BP, Schaffer M, Brody JD, Jurczak W, Carpio C, Ben-Yehuda D, Avivi I, Forslund A, Özcan M, Alvarez J, Ceulemans R, Fourneau N, Younes A, Balasubramanian S. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. Transl Oncol 2021;14:100977. [PMID: 33395752 DOI: 10.1016/j.tranon.2020.100977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
160 Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol 2020;10:594558. [PMID: 33324564 DOI: 10.3389/fonc.2020.594558] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
161 Michalka J, Janíková A, Král Z. Immunotherapy in the treatment of classic Hodgkin lymphoma. Onkologie 2020;14:221-225. [DOI: 10.36290/xon.2020.078] [Reference Citation Analysis]
162 Kubeček O, Kopecký J. Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie 2020;14:199-204. [DOI: 10.36290/xon.2020.074] [Reference Citation Analysis]
163 Joshi M, Ansell SM. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. J Immunol Res 2020;2020:8820377. [PMID: 33294467 DOI: 10.1155/2020/8820377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
164 Maruyama D, Terui Y, Yamamoto K, Fukuhara N, Choi I, Kuroda J, Ando K, Hattori A, Tobinai K. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol 2020;50:1265-73. [PMID: 32776097 DOI: 10.1093/jjco/hyaa117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
165 Lee Y, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JS, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH. Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotype.. [DOI: 10.1101/2020.11.07.372334] [Reference Citation Analysis]
166 Castagna L, Santoro A, Carlo-Stella C. Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes. J Blood Med 2020;11:389-403. [PMID: 33149713 DOI: 10.2147/JBM.S250581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Nagpal P, Descalzi-Montoya DB, Lodhi N. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes. Cancer Rep (Hoboken) 2021;4:e1311. [PMID: 33103852 DOI: 10.1002/cnr2.1311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
168 de Jonge AV, Mutis T, Roemer MGM, Scheijen B, Chamuleau MED. Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. Cancers (Basel) 2020;12:E3052. [PMID: 33092116 DOI: 10.3390/cancers12103052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
169 Voorhees TJ, Beaven AW. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers (Basel) 2020;12:E2887. [PMID: 33050054 DOI: 10.3390/cancers12102887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
170 Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:e105-11. [PMID: 33160934 DOI: 10.1016/j.clml.2020.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
171 Ikegawa S, Meguri Y, Kondo T, Sugiura H, Sando Y, Nakamura M, Iwamoto M, Maeda Y, Matsuoka KI. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade. Blood Adv 2019;3:4081-94. [PMID: 31821459 DOI: 10.1182/bloodadvances.2019000134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
172 Balzarotti M, Santoro A. Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? Ann Transl Med 2020;8:1035. [PMID: 32953835 DOI: 10.21037/atm.2020.04.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
173 Hu W, Wang G, Wang Y, Riese MJ, You M. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. iScience 2020;23:101580. [PMID: 33083746 DOI: 10.1016/j.isci.2020.101580] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
174 Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7:e660-e670. [PMID: 32853585 DOI: 10.1016/s2352-3026(20)30221-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 16.3] [Reference Citation Analysis]
175 Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Cavo M, Zinzani PL. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 2020;9:7830-6. [PMID: 32881376 DOI: 10.1002/cam4.3262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
176 Shannon VR, Anderson R, Blidner A, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson DB, Suarez-Almazor ME, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer 2020;28:6145-57. [PMID: 32880733 DOI: 10.1007/s00520-020-05708-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
177 Straus DJ. Treatment of Newly Diagnosed Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2020;20:S87-S88. [DOI: 10.1016/s2152-2650(20)30473-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Pugh M, Akarka AU, Hunter K, Dojcinov S, Marafioti T. Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment. Diagnostic Histopathology 2020;26:407-20. [DOI: 10.1016/j.mpdhp.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
179 Shan Q, Wang H, Han X, Guo J, Wang Z. Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. Thorac Cancer 2020;11:3001-6. [PMID: 32833320 DOI: 10.1111/1759-7714.13600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
180 Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol 2020;13:111. [PMID: 32787882 DOI: 10.1186/s13045-020-00947-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
181 Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol 2020;95:978-89. [PMID: 32384177 DOI: 10.1002/ajh.25856] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
182 Kuzume A, Chi S, Yamauchi N, Minami Y. Immune-Checkpoint Blockade Therapy in Lymphoma. Int J Mol Sci 2020;21:E5456. [PMID: 32751706 DOI: 10.3390/ijms21155456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
183 Donegani MI, Ferrarazzo G, Marra S, Miceli A, Raffa S, Bauckneht M, Morbelli S. Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina (Kaunas) 2020;56:E373. [PMID: 32722205 DOI: 10.3390/medicina56080373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
184 Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Hodgkin lymphoma. Nat Rev Dis Primers 2020;6:61. [PMID: 32703953 DOI: 10.1038/s41572-020-0189-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
185 Aurer I, Zing N, Federico M. Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines. HemaSphere 2020;4:e458. [DOI: 10.1097/hs9.0000000000000458] [Reference Citation Analysis]
186 Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, Atagi S. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. Clin Transl Oncol 2021;23:582-90. [PMID: 32661824 DOI: 10.1007/s12094-020-02452-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 2020;11:2406-30. [PMID: 32643323 DOI: 10.1111/1759-7714.13541] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
188 Guo L, Wei R, Lin Y, Kwok HF. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. Front Immunol 2020;11:1508. [PMID: 32733486 DOI: 10.3389/fimmu.2020.01508] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
189 Demina EA, Tumyan GS, Moiseeva TN, Mikhailova NB, Myakova NV, Rumyantsev AG, Maschan AA, Kaplanov KD, Shmakov RG, Falaleeva NA, Ptushkin VV, Osmanov EA, Poddubnaya IV, Baikov VV, Kovrigina AM, Konovalov DM, Trofimova OP, Sotnikov VM, Ilin NV, Vinogradova YN, Nechesnyuk AV, Parkhomenko RA, Stefanov DN, Nevolsky AA, Ivanov SA, Khaylova ZV. Hodgkin's lymphoma. J Mod Onco 2020;22:6-33. [DOI: 10.26442/18151434.2020.2.200132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
190 Hur JY, Yoon SE, Kim SJ, Kim WS. Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study. Blood Res 2020;55:85-90. [PMID: 32595170 DOI: 10.5045/br.2020.2020014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
191 Paul S, Zahurak M, Luznik L, Ambinder RF, Fuchs EJ, Bolaños-Meade J, Wagner-Johnston N, Swinnen LJ, Schoch L, Varadhan R, Jones RJ, Gladstone DE. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biol Blood Marrow Transplant 2020;26:1679-88. [PMID: 32592857 DOI: 10.1016/j.bbmt.2020.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
192 Lockney NA, Yang JC. Radiation Therapy for Advanced-Stage Hodgkin Lymphoma. Adv Radiat Oncol 2020;5:809-16. [PMID: 33083642 DOI: 10.1016/j.adro.2020.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
193 Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV. A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure. Hemasphere 2020;4:e401. [PMID: 32647803 DOI: 10.1097/HS9.0000000000000401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
194 Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Br J Clin Pharmacol 2020;86:1736-52. [PMID: 32384184 DOI: 10.1111/bcp.14352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
195 Di Renzo N, Gaudio F, Carlo Stella C, Oppi S, Pelosini M, Sorasio R, Stelitano C, Rigacci L. Relapsing/refractory HL after autotransplantation: which treatment? Acta Biomed 2020;91:30-40. [PMID: 32525132 DOI: 10.23750/abm.v91iS-5.9912] [Reference Citation Analysis]
196 Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers (Basel) 2020;12:E1303. [PMID: 32455666 DOI: 10.3390/cancers12051303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
197 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
198 Carter J, David KA, Kritharis A, Evens AM. Current Treatment Options for Older Patients with Hodgkin Lymphoma. Curr Treat Options Oncol 2020;21:42. [PMID: 32328822 DOI: 10.1007/s11864-020-00745-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
199 Rogado J, Romero-Laorden N, Sanchez-Torres JM, Ramos-Levi AM, Pacheco-Barcia V, Ballesteros AI, Arranz R, Lorenzo A, Gullon P, Garrido A, Serra López-Matencio JM, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondejar R, Colomer R. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Oncoimmunology 2020;9:1751548. [PMID: 32363123 DOI: 10.1080/2162402X.2020.1751548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
200 Kattan J, Kattan C, Assi T. Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection? Immunotherapy 2020;12:351-4. [PMID: 32290754 DOI: 10.2217/imt-2020-0077] [Cited by in Crossref: 25] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
201 Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers (Basel) 2020;12:E924. [PMID: 32290052 DOI: 10.3390/cancers12040924] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
202 Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP, Ponath G, Raddassi K, Huttner A, Hafler DA, Pitt D. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurol Neuroimmunol Neuroinflamm 2020;7:e712. [PMID: 32269065 DOI: 10.1212/NXI.0000000000000712] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
203 Karihtala K, Leivonen SK, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Pellinen T, Leppä S. Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. Cancers (Basel) 2020;12:E877. [PMID: 32260340 DOI: 10.3390/cancers12040877] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
204 Mora J, Modak S. Nivolumab in paediatric cancer: children are not little adults. Lancet Oncol 2020;21:474-6. [PMID: 32192574 DOI: 10.1016/S1470-2045(20)30086-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
205 Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020;21:541-50. [PMID: 32192573 DOI: 10.1016/S1470-2045(20)30023-1] [Cited by in Crossref: 116] [Cited by in F6Publishing: 125] [Article Influence: 38.7] [Reference Citation Analysis]
206 Patel SS, Weirather JL, Lipschitz M, Lako A, Chen PH, Griffin GK, Armand P, Shipp MA, Rodig SJ. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood 2019;134:2059-69. [PMID: 31697809 DOI: 10.1182/blood.2019002206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
207 Tanaka K, Kuboki M, Koi S, Toyota S. Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient. Intern Med 2020;59:829-33. [PMID: 31761888 DOI: 10.2169/internalmedicine.3772-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Yang W, Men P, Xue H, Jiang M, Luo Q. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:197. [PMID: 32211312 DOI: 10.3389/fonc.2020.00197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
209 Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 2020;5:15. [PMID: 32296035 DOI: 10.1038/s41392-020-0113-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
210 Kawashima M, Carreras J, Higuchi H, Kotaki R, Hoshina T, Okuyama K, Suzuki N, Kakizaki M, Miyatake Y, Ando K, Nakayama M, Umezu S, Horie R, Higuchi Y, Katagiri K, Goyama S, Kitamura T, Chamoto K, Yano S, Nakamura N, Kotani A. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia 2020;34:2405-17. [PMID: 32089543 DOI: 10.1038/s41375-020-0737-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
211 Poggi A. Hodgkin Disease. eLS 2020. [DOI: 10.1002/9780470015902.a0002170.pub2] [Reference Citation Analysis]
212 Vassilakopoulos TP, Asimakopoulos JV, Konstantopoulos K, Angelopoulou MK. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol 2020;11:2040620720902911. [PMID: 32110285 DOI: 10.1177/2040620720902911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
213 Zhang J, Fan L, Li JY. [Research progress of treatment in Hodgkin lymphoma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:969-72. [PMID: 31856452 DOI: 10.3760/cma.j.issn.0253-2727.2019.11.018] [Reference Citation Analysis]
214 Zinzani PL, Chen R, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Nahar A, Balakumaran A, Moskowitz CH. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma 2020;61:950-4. [PMID: 31905294 DOI: 10.1080/10428194.2019.1702178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
215 Roerden M, Sökler M, Kanz L, Bethge W, Vogel W, Walz JS. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience. Ann Hematol 2020;99:265-76. [PMID: 31897675 DOI: 10.1007/s00277-019-03900-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Zhao L, Yu J, Wang J, Li H, Che J, Cao B. Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. J Cancer 2020;11:41-50. [PMID: 31892971 DOI: 10.7150/jca.32724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
217 Bröckelmann PJ, Specht L. Prognostic Factors. Hodgkin Lymphoma 2020. [DOI: 10.1007/978-3-030-32482-7_8] [Reference Citation Analysis]
218 Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50009-7] [Reference Citation Analysis]
219 Merryman R, Armand P, Ansell S. Hodgkin Lymphoma and PD-1 Blockade. Hodgkin Lymphoma 2020. [DOI: 10.1007/978-3-030-32482-7_23] [Reference Citation Analysis]
220 Bartlett N, Triska G. Hodgkin Lymphoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00102-x] [Reference Citation Analysis]
221 Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol 2020;1248:33-59. [PMID: 32185706 DOI: 10.1007/978-981-15-3266-5_3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 33.3] [Reference Citation Analysis]
222 Aryan Z, Keshavarz-fathi M, Mellstedt H, Rezaei N. Cancer Immunotherapy Confers a Global Benefit. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_1] [Reference Citation Analysis]
223 Lin N, Song Y, Zhu J. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chin J Cancer Res 2020;32:303-18. [PMID: 32694896 DOI: 10.21147/j.issn.1000-9604.2020.03.03] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
224 Shi H, Lan J, Yang J. Mechanisms of Resistance to Checkpoint Blockade Therapy. Adv Exp Med Biol 2020;1248:83-117. [PMID: 32185708 DOI: 10.1007/978-981-15-3266-5_5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
225 Ebadi M, Keshavarz-fathi M, Zeng Y, Gkotzamanidou M, Rezaei N. Immunopathology and Immunotherapy of Hodgkin Lymphoma. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_6] [Reference Citation Analysis]
226 Kulkarni V, Sapkota S, Badarkhe GV, Srinivas B, Naik R. Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience. Indian Journal of Medical and Paediatric Oncology 2020;41:23-28. [DOI: 10.4103/ijmpo.ijmpo_64_19] [Reference Citation Analysis]
227 Ranganathan R, Shea TC. Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas. Novel Therapeutics for Rare Lymphomas 2020. [DOI: 10.1007/978-3-030-25610-4_3] [Reference Citation Analysis]
228 André MPE, Engert A. Treatment of Early Unfavorable Hodgkin Lymphoma. Hodgkin Lymphoma 2020. [DOI: 10.1007/978-3-030-32482-7_12] [Reference Citation Analysis]
229 Shah H, Jacene H. Therapy Response Imaging in Lymphoma and Hematologic Malignancies. Therapy Response Imaging in Oncology 2020. [DOI: 10.1007/978-3-030-31171-1_11] [Reference Citation Analysis]
230 Dobrenkov K, Cheung NV. Therapeutic Antibodies and Immunologic Conjugates. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00030-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Visser L, Veldman J, Poppema S, van den Berg A, Diepstra A. Microenvironment, Cross-Talk, and Immune Escape Mechanisms. Hodgkin Lymphoma 2020. [DOI: 10.1007/978-3-030-32482-7_4] [Reference Citation Analysis]
232 Bernasconi P, Borsani O. Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies. Cancers (Basel) 2019;12:E69. [PMID: 31881776 DOI: 10.3390/cancers12010069] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
233 Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510-519. [PMID: 31863227 DOI: 10.1007/s10120-019-01034-7] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 18.8] [Reference Citation Analysis]
234 Zhang X, Chen L, Zhao Y, Yin H, Ma H, He M. Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. Biomed Res Int 2019;2019:9283860. [PMID: 31950058 DOI: 10.1155/2019/9283860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
235 Lai C, Kandahari AM, Ujjani C. The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma. Blood Lymphat Cancer 2019;9:63-71. [PMID: 31849558 DOI: 10.2147/BLCTT.S231821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
236 Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program 2019;2019:252-9. [PMID: 31808838 DOI: 10.1182/hematology.2019000030] [Reference Citation Analysis]
237 Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist 2020;25:e398-404. [PMID: 32162817 DOI: 10.1634/theoncologist.2018-0883] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
238 Calabretta E, d'Amore F, Carlo-Stella C. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Int J Mol Sci 2019;20:E5503. [PMID: 31694167 DOI: 10.3390/ijms20215503] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
239 Wurm S, Spindelböck W. Medikamentös induzierte akute Pankreatitis. J Gastroenterol Hepatol Erkr 2019;17:101-107. [DOI: 10.1007/s41971-019-00061-6] [Reference Citation Analysis]
240 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
241 Jakobsen NA, Vyas P. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. Clin Med (Lond) 2018;18:s47-53. [PMID: 29700093 DOI: 10.7861/clinmedicine.18-2-s47] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
242 De Re V, Caggiari L, Repetto O, Mussolin L, Mascarin M. Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. J Clin Med 2019;8:E1596. [PMID: 31581738 DOI: 10.3390/jcm8101596] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
243 Ueno M, Doi A, Sunami T, Takayama H, Mouri H, Mizuno M. Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting. J Gastrointest Oncol. 2019;10:957-964. [PMID: 31602334 DOI: 10.21037/jgo.2019.05.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
244 Gillessen S, von Tresckow B. Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms. Info Onkol 2019;22:16-20. [DOI: 10.1007/s15004-019-6700-0] [Reference Citation Analysis]
245 Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Hodgkin Lymphoma in Adults. Dtsch Arztebl Int 2018;115:535-40. [PMID: 30149835 DOI: 10.3238/arztebl.2018.0535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
246 Momotow J, Goergen H, Behringer K, Bröckelmann PJ, Borchmann S, Tresckow BV, Kobe C, Engert A, Sasse S. Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center. Hemasphere 2019;3:e293. [PMID: 31942546 DOI: 10.1097/HS9.0000000000000293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
247 Grywalska E, Sobstyl M, Putowski L, Roliński J. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. Int J Mol Sci 2019;20:E4705. [PMID: 31547532 DOI: 10.3390/ijms20194705] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
248 Forbes SG, Mistry HE. Immune-Mediated Therapies in Lymphoma. Semin Oncol Nurs 2019;35:150925. [PMID: 31526549 DOI: 10.1016/j.soncn.2019.08.004] [Reference Citation Analysis]
249 Pönisch W, Alten R, Baerwald C. [Autoimmune reactions to immune checkpoint inhibitors]. Z Rheumatol 2017;76:57-62. [PMID: 29330759 DOI: 10.1007/s00393-017-0368-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
250 Cassaday RD, Press OW, Pagel JM, Rajendran JG, Gooley TA, Fisher DR, Holmberg LA, Miyaoka RS, Sandmaier BM, Green DJ, Gopal AK. Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. Clin Cancer Res 2019;25:6932-8. [PMID: 31481510 DOI: 10.1158/1078-0432.CCR-19-1567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
251 Clarke JM, George DJ, Lisi S, Salama AKS. Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Target Oncol 2018;13:1-20. [PMID: 29441437 DOI: 10.1007/s11523-017-0549-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
252 Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, Link BK, Ansell SM, Cerhan JR, Novak AJ. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J 2019;9:73. [PMID: 31471540 DOI: 10.1038/s41408-019-0233-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
253 Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist 2019;24:1488-95. [PMID: 31467178 DOI: 10.1634/theoncologist.2019-0172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
254 Alhashmi H, Kandil M, Alhejazi A, Motabi I, Sagheir A, Alzahrani M, Dada R, Al-Mansour M. Hodgkin's Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up. Saudi J Med Med Sci 2019;7:195-201. [PMID: 31543744 DOI: 10.4103/sjmms.sjmms_96_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
255 Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2018;2:2226-9. [PMID: 30190282 DOI: 10.1182/bloodadvances.2018019208] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
256 Rivas MM, Berro M, Prates MV, Yantorno S, Fiad L, Arbelbide JA, Basquiera AL, Ferini GA, García JJ, García PA, Riera L, Jarchum G, Baso A, Real J, Castro M, Jaimovich G, Martinez Rolón J, Foncuberta C, Saba S, Kusminsky G; GATMO (Grupo Argentino de Trasplante de Médula Ósea). Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transplant 2020;55:117-25. [PMID: 31435033 DOI: 10.1038/s41409-019-0640-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
257 Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019;134:1144-53. [PMID: 31409671 DOI: 10.1182/blood.2019000324] [Cited by in Crossref: 168] [Cited by in F6Publishing: 179] [Article Influence: 42.0] [Reference Citation Analysis]
258 Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, Arapaki M, Tzoras E, Angelopoulou MK, Konstantopoulos K. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers (Basel) 2019;11:E1071. [PMID: 31362369 DOI: 10.3390/cancers11081071] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
259 Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, Arapaki M, Tzoras E, Angelopoulou MK, Konstantopoulos K. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers (Basel). 2019;11:1071. [PMID: 31362369 DOI: 10.3390/cancers] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
260 Gómez-almaguer D, González-llano O, Jiménez-antolinez V, Gómez-de León A. Treatment of classical Hodgkin’s lymphoma in children and adolescents. Expert Opinion on Pharmacotherapy 2019;20:1227-1234. [DOI: 10.1080/14656566.2019.1606212] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
261 Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:59. [PMID: 31186046 DOI: 10.1186/s13045-019-0746-1] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 17.8] [Reference Citation Analysis]
262 Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel Immunotherapies for T Cell Lymphoma and Leukemia. Curr Hematol Malig Rep 2018;13:494-506. [PMID: 30317410 DOI: 10.1007/s11899-018-0480-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
263 Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, Pinto A. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Front Oncol 2019;9:443. [PMID: 31214498 DOI: 10.3389/fonc.2019.00443] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
264 George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology 2019;19:587-94. [PMID: 31076344 DOI: 10.1016/j.pan.2019.04.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
265 Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant 2019;25:1859-68. [PMID: 31132455 DOI: 10.1016/j.bbmt.2019.05.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
266 Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019;17:661-674. [PMID: 31205619 DOI: 10.1016/j.csbj.2019.03.006] [Cited by in Crossref: 194] [Cited by in F6Publishing: 216] [Article Influence: 48.5] [Reference Citation Analysis]
267 Trommer M, Yeo SY, Persigehl T, Bunck A, Grüll H, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Herter JM, Celik E, Marnitz S, Baues C. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol 2019;10:511. [PMID: 31156434 DOI: 10.3389/fphar.2019.00511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
268 Carbone A, Gloghini A, Pruneri G, Dolcetti R. Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. Cancer Med 2019;8:3012-6. [PMID: 31070022 DOI: 10.1002/cam4.2168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
269 De Goycoechea D, Stalder G, Martins F, Duchosal MA. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives. J Oncol 2019;2019:9513701. [PMID: 31205470 DOI: 10.1155/2019/9513701] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
270 Carreau NA, Diefenbach CS. Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist. Ther Adv Hematol 2019;10:2040620719846451. [PMID: 31105921 DOI: 10.1177/2040620719846451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
271 Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, Zhao H, Zhang L. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. Oncologist 2019;24:891-e431. [PMID: 31048330 DOI: 10.1634/theoncologist.2019-0284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
272 Zhou H, Fu X, Li Q, Niu T. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. Front Pharmacol 2019;10:387. [PMID: 31118893 DOI: 10.3389/fphar.2019.00387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
273 Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 2019;54:538-45. [PMID: 31079556 DOI: 10.1080/00365521.2019.1594356] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
274 Magnuson A, Elias R, Koll T. Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. J Am Geriatr Soc 2019;67:1012-9. [PMID: 31034592 DOI: 10.1111/jgs.15943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
275 Wen WX, Leong CO. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS One 2019;14:e0215381. [PMID: 31022191 DOI: 10.1371/journal.pone.0215381] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 12.5] [Reference Citation Analysis]
276 Tomassetti S, Chen R, Dandapani S. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Ther Adv Hematol 2019;10:2040620719841591. [PMID: 31040936 DOI: 10.1177/2040620719841591] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
277 Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ. Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. Radiother Oncol 2019;134:89-95. [PMID: 31005229 DOI: 10.1016/j.radonc.2019.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Jiang X, Li L, Li Y, Li Q. Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. J Cancer 2019;10:1764-71. [PMID: 31205532 DOI: 10.7150/jca.26481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
279 Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Blum KA, Lohse CM, Hakimi AA, Thompson RH, Leibovich BC, Berger MF, Arcila ME, Ross DS, Ladanyi M, Antonescu CR, Reuter VE. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Mod Pathol 2019;32:1344-58. [PMID: 30996253 DOI: 10.1038/s41379-019-0269-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
280 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 27.0] [Reference Citation Analysis]
281 Charles J, Giovannini D, Terzi N, Schwebel C, Sturm N, Masson D, Leccia MT, Cahn JY, Manches O, Bulabois CE, Chaperot L. Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation. Exp Hematol Oncol 2019;8:8. [PMID: 30963019 DOI: 10.1186/s40164-019-0132-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
282 Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer 2019;19:273. [PMID: 30917792 DOI: 10.1186/s12885-019-5466-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
283 Lucca LE, Lerner BA, Debartolo D, Park C, Ponath G, Raddassi K, Hafler DA, Pitt D. Differential Expression of the T cell Inhibitor TIGIT in Glioblastoma and Multiple Sclerosis.. [DOI: 10.1101/591131] [Reference Citation Analysis]
284 Mina AA, Vakkalagadda C, Pro B. Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy. Cancers (Basel) 2019;11:E421. [PMID: 30934568 DOI: 10.3390/cancers11030421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
285 van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8. [PMID: 29875199 DOI: 10.1098/rsob.180037] [Cited by in Crossref: 89] [Cited by in F6Publishing: 96] [Article Influence: 22.3] [Reference Citation Analysis]
286 Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS. Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Adv 2018;2:1547-50. [PMID: 29970391 DOI: 10.1182/bloodadvances.2018021071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
287 Deng M. The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China. Antib Ther 2019;2:54-5. [PMID: 33928222 DOI: 10.1093/abt/tbz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
288 Zhu HB, Deng Q, Zhang R, Jiang YY, Meng JX, Zhao MF, Li YM, Cui R. [Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells]. Zhonghua Xue Ye Xue Za Zhi 2018;39:584-8. [PMID: 30122019 DOI: 10.3760/cma.j.issn.0253-2727.2018.07.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J 2019;9:22. [PMID: 30783096 DOI: 10.1038/s41408-019-0185-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
290 Moskowitz CH. Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2018;2:821-4. [PMID: 29636328 DOI: 10.1182/bloodadvances.2017011130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
291 Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv 2018;2:817-20. [PMID: 29636327 DOI: 10.1182/bloodadvances.2017011122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
292 Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Arch 2019;474:421-32. [PMID: 30747264 DOI: 10.1007/s00428-019-02538-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
293 Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7:31. [PMID: 30728076 DOI: 10.1186/s40425-019-0502-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
294 Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol Res 2019;7:355-62. [PMID: 30659053 DOI: 10.1158/2326-6066.CIR-18-0351] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 14.5] [Reference Citation Analysis]
295 Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 2018;20:674-86. [PMID: 29106665 DOI: 10.1093/neuonc/nox208] [Cited by in Crossref: 252] [Cited by in F6Publishing: 266] [Article Influence: 63.0] [Reference Citation Analysis]
296 Herrera AF. Where does PD-1 blockade fit in HL therapy? Hematology Am Soc Hematol Educ Program 2018;2018:213-20. [PMID: 30504313 DOI: 10.1182/asheducation-2018.1.213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
297 Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2018;2018:200-6. [PMID: 30504311 DOI: 10.1182/asheducation-2018.1.200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
298 Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793-802. [PMID: 30627987 DOI: 10.1007/s10120-018-00922-8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 21.3] [Reference Citation Analysis]
299 Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol 2019;37:481-9. [PMID: 30620669 DOI: 10.1200/JCO.18.00766] [Cited by in Crossref: 180] [Cited by in F6Publishing: 189] [Article Influence: 45.0] [Reference Citation Analysis]
300 Sawalha Y, Advani A. Hematologic Malignancies. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00009-3] [Reference Citation Analysis]
301 Kalinski P, Basse P. Immune Checkpoint Inhibitors. Immune Checkpoint Inhibitors in Cancer 2019. [DOI: 10.1016/b978-0-323-54948-6.00001-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
302 Dutta D, Lim SH. Pharmacoepigenetics of Acute Myeloid Leukemia. Pharmacoepigenetics 2019. [DOI: 10.1016/b978-0-12-813939-4.00016-4] [Reference Citation Analysis]
303 Koeppen H, Mccleland ML, Kowanetz M. Predictive Biomarkers and Targeted Therapies in Immuno-oncology. Predictive Biomarkers in Oncology 2019. [DOI: 10.1007/978-3-319-95228-4_29] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. J Oncol 2019;2019:2989048. [PMID: 31275380 DOI: 10.1155/2019/2989048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
305 Keshavarz-fathi M, Rezaei N. Immunotherapeutic Approaches in Cancer. Vaccines for Cancer Immunotherapy 2019. [DOI: 10.1016/b978-0-12-814039-0.00002-3] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
306 Mititelu A, Andruş-lupoaia E, Onisâi MC, Spînu A, Dobre C, Tănase A, Bumbăcea D, Vlădăreanu AM. A challenging case of relapsed refractory classical Hodgkin’s lymphoma – nodular sclerosis. Oncolog-Hematolog ro 2019;1:36. [DOI: 10.26416/onhe.46.1.2019.2313] [Reference Citation Analysis]
307 Murshed H. Immunotherapy. Fundamentals of Radiation Oncology 2019. [DOI: 10.1016/b978-0-12-814128-1.00010-6] [Reference Citation Analysis]
308 Vassilakopoulos TP, Böll B, Department of Haematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Greece, Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany. Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care. European Oncology & Haematology 2019;15:53. [DOI: 10.17925/eoh.2019.15.1.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Malesa A, Nowak J, Skórka K, Karp M, Giannopoulos K. Immunoterapia z użyciem przeciwciał monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. Acta Haematologica Polonica 2018;49:207-227. [DOI: 10.2478/ahp-2018-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
310 Długosz-danecka M, Szymczyk M, Fischer J, Łojko-dankowska A, Rybka J, Mańko J, Duda K, Jurczak W. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience. Acta Haematologica Polonica 2018;49:228-233. [DOI: 10.2478/ahp-2018-0026] [Reference Citation Analysis]
311 Farris JC, Ritter A, Craig MD, Shah N, Veltri L, Kanate AS, Ross K, Vargo JA. Patterns of Relapse After Salvage Autologous Stem Cell Transplant for Hodgkin's Lymphoma: Should Sites of Relapse Relative to Initially Involved Sites Be Used to Guide Indications for Peri-Transplant Radiation Therapy. Pract Radiat Oncol 2019;9:e290-7. [PMID: 30579808 DOI: 10.1016/j.prro.2018.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 Kwon M, Choi YJ, Sa M, Park SH, Shin EC. Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. Immune Netw 2018;18:e45. [PMID: 30619631 DOI: 10.4110/in.2018.18.e45] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
313 Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist 2019;24:955-62. [PMID: 30568021 DOI: 10.1634/theoncologist.2018-0538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
314 Gupta S, Vanderbilt CM, Cotzia P, Arias-Stella JA 3rd, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. J Mol Diagn 2019;21:307-17. [PMID: 30576871 DOI: 10.1016/j.jmoldx.2018.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
315 Pan M, Alavi M, Herrinton LJ. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Perm J 2018;22:17-149. [PMID: 29616914 DOI: 10.7812/TPP/17-149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
316 Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A. Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. BMC Cancer 2018;18:1209. [PMID: 30514251 DOI: 10.1186/s12885-018-5111-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
317 Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 2019;125:1470-81. [PMID: 30500073 DOI: 10.1002/cncr.31896] [Cited by in Crossref: 134] [Cited by in F6Publishing: 146] [Article Influence: 26.8] [Reference Citation Analysis]
318 Furubayashi N, Negishi T, Uozumi T, Takamatsu D, Shiraishi K, Hirose D, Nakamura M. Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. Mol Clin Oncol 2019;10:304-8. [PMID: 30680212 DOI: 10.3892/mco.2018.1781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
319 Depaus J, Delcourt A, André M. Therapeutic recommendations for early stage Hodgkin lymphomas. Br J Haematol 2019;184:9-16. [PMID: 30485401 DOI: 10.1111/bjh.15623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
320 Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity 2018;48:434-52. [PMID: 29562194 DOI: 10.1016/j.immuni.2018.03.014] [Cited by in Crossref: 864] [Cited by in F6Publishing: 922] [Article Influence: 172.8] [Reference Citation Analysis]
321 Bröckelmann PJ, Böll B. Moving things forward in Hodgkin lymphoma. F1000Res 2018;7:F1000 Faculty Rev-1786. [PMID: 30473768 DOI: 10.12688/f1000research.16077.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
322 Kaloyannidis P, Al Shaibani E, Mashhour M, Gamil M, Apostolidis I, Al Hashmi H, Al Anazi KA. De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation. Case Rep Hematol 2018;2018:6215958. [PMID: 30410803 DOI: 10.1155/2018/6215958] [Reference Citation Analysis]
323 Hirsch L, Zitvogel L, Eggermont A, Marabelle A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Cancer. 2019;120:3-5. [PMID: 30413824 DOI: 10.1038/s41416-018-0294-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
324 Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol 2019;184:45-59. [PMID: 30407610 DOI: 10.1111/bjh.15614] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
325 Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers (Basel) 2018;10:E415. [PMID: 30384489 DOI: 10.3390/cancers10110415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
326 Paul B, Kang S, Zheng Z, Kang Y. The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cell Immunol 2018;334:87-98. [PMID: 30342750 DOI: 10.1016/j.cellimm.2018.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
327 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 2018;109:3583-90. [PMID: 30230649 DOI: 10.1111/cas.13800] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
328 Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. J Clin Oncol 2018;:JCO1800122. [PMID: 30285558 DOI: 10.1200/JCO.18.00122] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
329 Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. J Immunother Cancer 2018;6:101. [PMID: 30285872 DOI: 10.1186/s40425-018-0421-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
330 Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A. Controversies in the Treatment of Classical Hodgkin Lymphoma. Hemasphere 2018;2:e149. [PMID: 30887012 DOI: 10.1097/HS9.0000000000000149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
331 Hollander P, Amini RM, Ginman B, Molin D, Enblad G, Glimelius I. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. PLoS One 2018;13:e0204870. [PMID: 30261066 DOI: 10.1371/journal.pone.0204870] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
332 Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunol Res 2018;6:1511-23. [PMID: 30242021 DOI: 10.1158/2326-6066.CIR-18-0193] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
333 Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA 3rd, Chang JC, Chen Y, Tang LH, DeLair DF, Yao J, Ladanyi M, Ross DS. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Hum Pathol 2019;88:87-91. [PMID: 30236595 DOI: 10.1016/j.humpath.2018.08.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
334 LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 2018;200:375-83. [PMID: 29311378 DOI: 10.4049/jimmunol.1701044] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 17.0] [Reference Citation Analysis]
335 Kirienko M, Sollini M, Chiti A. Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. Clin Transl Imaging 2018;6:417-27. [DOI: 10.1007/s40336-018-0294-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
336 Vardhana S, Cicero K, Velez MJ, Moskowitz CH. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Oncologist 2019;24:86-95. [PMID: 30082490 DOI: 10.1634/theoncologist.2018-0045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
337 Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. Haematologica 2019;104:e21-4. [PMID: 30076177 DOI: 10.3324/haematol.2018.196279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
338 Johnson CB, Ong M. Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity? Canadian Journal of Cardiology 2018;34:970-971. [DOI: 10.1016/j.cjca.2018.04.010] [Reference Citation Analysis]
339 Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132:1013-21. [PMID: 30049811 DOI: 10.1182/blood-2018-01-827246] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
340 Hallam S. Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma. Hemasphere 2018;2:e137. [PMID: 31723786 DOI: 10.1097/HS9.0000000000000137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
341 Bartlett NL. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. Hematology Am Soc Hematol Educ Program 2017;2017:317-23. [PMID: 29222273 DOI: 10.1182/asheducation-2017.1.317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
342 Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2017;2017:310-6. [PMID: 29222272 DOI: 10.1182/asheducation-2017.1.310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
343 Ansell SM. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond. Hematology Am Soc Hematol Educ Program 2017;2017:618-21. [PMID: 29222312 DOI: 10.1182/asheducation-2017.1.618] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
344 Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). Cochrane Database Syst Rev 2018;7:CD012556. [PMID: 30001476 DOI: 10.1002/14651858.CD012556.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
345 Grover NS, Savoldo B. Targeting Immune System Alterations in Hodgkin Lymphoma. Curr Hematol Malig Rep 2017;12:358-69. [PMID: 28780614 DOI: 10.1007/s11899-017-0398-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
346 Xu PP, Sun C, Cao X, Zhao X, Dai HJ, Lu S, Guo JJ, Fu SJ, Liu YX, Li SC, Chen M, McCord R, Venstrom J, Szafer-Glusman E, Punnoose E, Kiermaier A, Cheng G, Zhao WL. Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. EBioMedicine 2018;33:94-104. [PMID: 29936139 DOI: 10.1016/j.ebiom.2018.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
347 Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res 2017;23:4950-8. [PMID: 28864723 DOI: 10.1158/1078-0432.CCR-16-3079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
348 Meti N, Esfahani K, Johnson NA. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers (Basel) 2018;10:E204. [PMID: 29914088 DOI: 10.3390/cancers10060204] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
349 Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 2018;6:46. [PMID: 29866197 DOI: 10.1186/s40425-018-0361-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 16.6] [Reference Citation Analysis]
350 Borcherding N, Kolb R, Gullicksrud J, Vikas P, Zhu Y, Zhang W. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 2018;430:2014-29. [PMID: 29800567 DOI: 10.1016/j.jmb.2018.05.030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
351 Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac Dis 2018;10:S1482-93. [PMID: 29951300 DOI: 10.21037/jtd.2018.05.106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
352 Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018;93:704-15. [PMID: 29634090 DOI: 10.1002/ajh.25071] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
353 Wang Y, Nowakowski GS, Wang ML, Ansell SM. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol 2018;11:57. [PMID: 29685160 DOI: 10.1186/s13045-018-0601-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
354 Watanabe T, Okuda K, Murase T, Moriyama S, Haneda H, Kawano O, Yokota K, Sakane T, Oda R, Inagaki H, Nakanishi R. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 2018;9:20769-80. [PMID: 29755688 DOI: 10.18632/oncotarget.25100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
355 Greil R, Pleyer L, Jansko B, Feierabend C, Rettenbacher L, Stiefel O, Rass C, Morre P, Neureiter D, Greil-Ressler S. Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. Oncotarget 2018;9:20928-40. [PMID: 29755699 DOI: 10.18632/oncotarget.25037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
356 Witkowska M, Smolewski P. Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. J Immunol Res 2018;2018:1982423. [PMID: 29850620 DOI: 10.1155/2018/1982423] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
357 Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol 2018;15:222-34. [PMID: 29512649 DOI: 10.1038/nrgastro.2018.14] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
358 Bröckelmann PJ, von Tresckow B, Engert A. Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom. Onkologe 2018;24:322-328. [DOI: 10.1007/s00761-018-0336-9] [Reference Citation Analysis]
359 Sasse S, Bröckelmann PJ, Baues C, Eich HT, Engert A. Therapie des Hodgkin-Lymphoms in frühen und intermediären Stadien. Onkologe 2018;24:303-314. [DOI: 10.1007/s00761-018-0345-8] [Reference Citation Analysis]
360 Niels Asger Jakobsen, Paresh Vyas. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. Clin Med (Lond) 2018;18. [PMID: 29700093 DOI: 10.7861/clinmedicine.18-2s-s47] [Reference Citation Analysis]
361 Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428-1439. [PMID: 29584546 DOI: 10.1200/jco.2017.76.0793] [Cited by in Crossref: 394] [Cited by in F6Publishing: 424] [Article Influence: 78.8] [Reference Citation Analysis]
362 Brice P. Refractory Hodgkin lymphoma: time for targeted therapies? Blood 2018;131:1156-1157. [DOI: 10.1182/blood-2017-12-824136] [Reference Citation Analysis]
363 Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, Dufour C, Kröger N, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2018;53:1139-48. [PMID: 29540849 DOI: 10.1038/s41409-018-0153-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 18.8] [Reference Citation Analysis]
364 Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018;4:1-7. [PMID: 29756118 DOI: 10.1016/j.cdtm.2017.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
365 Menter T, Tzankov A. Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. Front Oncol 2018;8:54. [PMID: 29564225 DOI: 10.3389/fonc.2018.00054] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
366 Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018;23:410-420. [PMID: 29516216 DOI: 10.1007/s10147-018-1259-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
367 Shindiapina P, Alinari L. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. Ther Adv Hematol 2018;9:89-105. [PMID: 29623180 DOI: 10.1177/2040620718761777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
368 Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood 2018;131:1698-703. [PMID: 29500171 DOI: 10.1182/blood-2017-09-772681] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
369 Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 2018;24:1602-9. [PMID: 29501779 DOI: 10.1016/j.bbmt.2018.02.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
370 Perez-Callejo D, Zurutuza L, Royuela A, Torrente M, Núñez B, Calvo V, Méndez M, Franco F, Brenes MA, Sánchez JC, Provencio M. Long-term follow up of Hodgkin lymphoma. Oncotarget 2018;9:11638-45. [PMID: 29545926 DOI: 10.18632/oncotarget.24392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
371 Hu H, Zhu Q, Luo XS, Yang XW, Wang HD, Guo CY. Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. Oncotarget 2018;9:11846-57. [PMID: 29545941 DOI: 10.18632/oncotarget.24163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
372 Moy RH, Younes A. Immune Checkpoint Inhibition in Hodgkin Lymphoma. Hemasphere 2018;2:e20. [PMID: 31723749 DOI: 10.1097/HS9.0000000000000020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
373 Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 2018;131:1809-19. [PMID: 29449276 DOI: 10.1182/blood-2017-07-796342] [Cited by in Crossref: 172] [Cited by in F6Publishing: 180] [Article Influence: 34.4] [Reference Citation Analysis]
374 Chumsri S, Knutson KL. Translation in Immunology. Immunotherapy in Translational Cancer Research 2018. [DOI: 10.1002/9781118684535.ch1] [Reference Citation Analysis]
375 Chiu J, Ernst DM, Keating A. Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Front Immunol 2018;9:267. [PMID: 29491867 DOI: 10.3389/fimmu.2018.00267] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
376 Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 2018;36:942-50. [PMID: 29394125 DOI: 10.1200/JCO.2017.77.3994] [Cited by in Crossref: 199] [Cited by in F6Publishing: 207] [Article Influence: 39.8] [Reference Citation Analysis]
377 Shi Y. Current status and progress of lymphoma management in China. Int J Hematol 2018;107:405-12. [PMID: 29388166 DOI: 10.1007/s12185-018-2404-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
378 Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436-1447. [PMID: 28379322 DOI: 10.1093/annonc/mdx097] [Cited by in Crossref: 154] [Cited by in F6Publishing: 166] [Article Influence: 30.8] [Reference Citation Analysis]
379 Faugeras L, Pirson AS, Donckier J, Michel L, Lemaire J, Vandervorst S, D'Hondt L. Refractory thyroid carcinoma: which systemic treatment to use? Ther Adv Med Oncol 2018;10:1758834017752853. [PMID: 29399055 DOI: 10.1177/1758834017752853] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
380 Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8. [PMID: 29357948 DOI: 10.1186/s40425-018-0316-z] [Cited by in Crossref: 660] [Cited by in F6Publishing: 707] [Article Influence: 132.0] [Reference Citation Analysis]
381 Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 2018;36:1128-39. [PMID: 29315015 DOI: 10.1200/JCO.2017.74.3179] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 20.6] [Reference Citation Analysis]
382 Chang E, Rivero G, Patel NR, Chiao EY, Lai S, Bajaj K, Mbue JE, Yellapragada SV. HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clin Lymphoma Myeloma Leuk 2018;18:e143-6. [PMID: 29342442 DOI: 10.1016/j.clml.2017.12.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
383 Vassilakopoulos TP, Prassopoulos VK. The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications. Imaging in Clinical Oncology 2018. [DOI: 10.1007/978-3-319-68873-2_94] [Reference Citation Analysis]
384 Lepik KV. Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Клиническая онкогематология 2018;11:303-312. [DOI: 10.21320/2500-2139-2018-11-4-303-312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
385 Heyman B, Yang Y. New developments in immunotherapy for lymphoma. Cancer Biol Med 2018;15:189-209. [PMID: 30197788 DOI: 10.20892/j.issn.2095-3941.2018.0037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
386 Facchinetti F, Gnetti L, Tiseo M. Therapy: Recommendations for the Oncologists. Current Clinical Pathology 2018. [DOI: 10.1007/978-3-319-90368-2_8] [Reference Citation Analysis]
387 Routy B, Ghez D. Current Status of Immuno-Oncology in Hematologic Cancers. Oncoimmunology 2018. [DOI: 10.1007/978-3-319-62431-0_38] [Reference Citation Analysis]
388 Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15:116-123. [PMID: 29951336 DOI: 10.20892/j.issn.2095-3941.2017.0086] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
389 Fricke U, Hein L, Schwabe U. Neue Arzneimittel 2017. Arzneiverordnungs-Report 2018 2018. [DOI: 10.1007/978-3-662-57386-0_3] [Reference Citation Analysis]
390 Engert A, Goergen H, Markova J, Pabst T, Meissner J, Zijlstra JM, Král Z, Eichenauer DA, Soekler M, Greil R, Kreissl S, Scheuvens R, Eich H, Kobe C, Dietlein M, Stein H, Fuchs M, Diehl V, Borchmann P. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group. Hemasphere 2017;1:e5. [PMID: 31723734 DOI: 10.1097/HS9.0000000000000005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
391 Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother 2018;14:269-76. [PMID: 29194007 DOI: 10.1080/21645515.2017.1403694] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
392 Ghosh A, Politikos I, Perales MA. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. Curr Opin Oncol 2017;29:474-83. [PMID: 28872470 DOI: 10.1097/CCO.0000000000000408] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
393 Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Haematologica 2018;103:1018-28. [PMID: 29242302 DOI: 10.3324/haematol.2017.174177] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
394 Chang A, Schlafer D, Flowers CR, Allen PB. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opin Investig Drugs 2018;27:55-70. [PMID: 29228840 DOI: 10.1080/13543784.2018.1416091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
395 Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 2017;130:2265-70. [PMID: 29167175 DOI: 10.1182/blood-2017-06-781989] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
396 Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv 2017;1:2643-54. [PMID: 29296917 DOI: 10.1182/bloodadvances.2017012534] [Cited by in Crossref: 67] [Cited by in F6Publishing: 78] [Article Influence: 11.2] [Reference Citation Analysis]
397 Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183-1194. [PMID: 29229594 DOI: 10.1182/blood-2017-10-811224] [Cited by in Crossref: 207] [Cited by in F6Publishing: 230] [Article Influence: 34.5] [Reference Citation Analysis]
398 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 25.3] [Reference Citation Analysis]
399 Füreder T. Immuntherapie in der Onkologie. Wien Klin Wochenschr Educ 2017;12:17-33. [DOI: 10.1007/s11812-017-0089-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
400 Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 2018;68:116-32. [PMID: 29194581 DOI: 10.3322/caac.21438] [Cited by in Crossref: 197] [Cited by in F6Publishing: 210] [Article Influence: 32.8] [Reference Citation Analysis]
401 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 182] [Cited by in F6Publishing: 203] [Article Influence: 30.3] [Reference Citation Analysis]
402 Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol 2017;10:174. [PMID: 29195503 DOI: 10.1186/s13045-017-0541-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 77] [Article Influence: 10.5] [Reference Citation Analysis]
403 Cooper MR, Almalki B, Willett KC. Nivolumab for the Treatment of Classical Hodgkin Lymphoma. Journal of Pharmacy Technology 2017;33:237-244. [DOI: 10.1177/8755122517716472] [Reference Citation Analysis]
404 Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S. Clinical significance of tryptophan catabolism in Hodgkin lymphoma. Cancer Sci 2018;109:74-83. [PMID: 29080383 DOI: 10.1111/cas.13432] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
405 Giulino-Roth L, O'Donohue T, Chen Z, Trippett TM, Klein E, Kernan NA, Kobos R, Prockop SE, Scaradavou A, Shukla N, Steinherz PG, Moskowitz AJ, Moskowitz CH, Boulad F. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 2018;59:1861-70. [PMID: 29183202 DOI: 10.1080/10428194.2017.1403601] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
406 Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 2018;131:68-83. [PMID: 29118007 DOI: 10.1182/blood-2017-07-740993] [Cited by in Crossref: 213] [Cited by in F6Publishing: 228] [Article Influence: 35.5] [Reference Citation Analysis]
407 Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F. A Review of Autologous Stem Cell Transplantation in Lymphoma. Curr Hematol Malig Rep 2017;12:217-26. [PMID: 28478586 DOI: 10.1007/s11899-017-0382-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
408 Khan N, Moskowitz AJ. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma? Curr Hematol Malig Rep 2017;12:227-33. [PMID: 28488185 DOI: 10.1007/s11899-017-0384-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
409 Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. [PMID: 29093678 DOI: 10.3389/fphar.2017.00730] [Cited by in Crossref: 231] [Cited by in F6Publishing: 249] [Article Influence: 38.5] [Reference Citation Analysis]
410 Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-33. [PMID: 29023213 DOI: 10.1200/JCO.2017.74.3062] [Cited by in Crossref: 473] [Cited by in F6Publishing: 545] [Article Influence: 78.8] [Reference Citation Analysis]
411 Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23:1028-1035. [PMID: 28886003 DOI: 10.1038/nm.4389] [Cited by in Crossref: 195] [Cited by in F6Publishing: 201] [Article Influence: 32.5] [Reference Citation Analysis]
412 Hindié E, Mesguich C, Bouabdallah K, Milpied N. Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”. Eur J Nucl Med Mol Imaging 2017;44:1937-1939. [DOI: 10.1007/s00259-017-3773-6] [Reference Citation Analysis]
413 Merryman RW, Armand P. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Curr Hematol Malig Rep 2017;12:44-50. [PMID: 28155012 DOI: 10.1007/s11899-017-0362-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
414 Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab 2017;102:2770-80. [PMID: 28609832 DOI: 10.1210/jc.2017-00448] [Cited by in Crossref: 127] [Cited by in F6Publishing: 140] [Article Influence: 21.2] [Reference Citation Analysis]
415 Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica 2017;102:1748-57. [PMID: 28912173 DOI: 10.3324/haematol.2017.167478] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
416 Pianko MJ, Moskowitz AJ, Lesokhin AM. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 2018;24:1002-10. [PMID: 28899972 DOI: 10.1158/1078-0432.CCR-17-0539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
417 Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130:2420-2430. [PMID: 28893733 DOI: 10.1182/blood-2017-03-770719] [Cited by in Crossref: 190] [Cited by in F6Publishing: 210] [Article Influence: 31.7] [Reference Citation Analysis]
418 Das S, Horn L. Quality matters: immunotherapy and the evolving landscape of advanced cancer care. Expert Review of Quality of Life in Cancer Care 2017;2:235-244. [DOI: 10.1080/23809000.2017.1381563] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
419 Scheuvens R. Immuntherapie beim Hodgkin-Lymphom. Info Onkol 2017;20:36-42. [DOI: 10.1007/s15004-017-5791-8] [Reference Citation Analysis]
420 Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Am J Hematol 2017;92:879-84. [PMID: 28512788 DOI: 10.1002/ajh.24792] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
421 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
422 Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2018;15:31-46. [PMID: 28857075 DOI: 10.1038/nrclinonc.2017.128] [Cited by in Crossref: 300] [Cited by in F6Publishing: 316] [Article Influence: 50.0] [Reference Citation Analysis]
423 Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol 2017;8:293-302. [PMID: 29051800 DOI: 10.1177/2040620717728000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
424 Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther 2017;6:51-71. [PMID: 28894725 DOI: 10.2147/ITT.S141577] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 12.7] [Reference Citation Analysis]
425 Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer 2017;5:66. [PMID: 28807048 DOI: 10.1186/s40425-017-0273-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
426 Johnson P, Longley J. Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma? Curr Treat Options Oncol 2017;18:15. [PMID: 28286922 DOI: 10.1007/s11864-017-0460-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
427 Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 2017;127:3462-71. [PMID: 28805662 DOI: 10.1172/JCI94306] [Cited by in Crossref: 225] [Cited by in F6Publishing: 236] [Article Influence: 37.5] [Reference Citation Analysis]
428 Rossides N. Shifting Treatment Paradigms in Non-Hodgkin Lymphomas. EMJ Hematol 2017. [DOI: 10.33590/emjhematol/10310138] [Reference Citation Analysis]
429 Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 2017;152:357-71. [PMID: 28685821 DOI: 10.1111/imm.12788] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 14.7] [Reference Citation Analysis]
430 Liu KG, Gupta S, Goel S. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget 2017;8:17313-27. [PMID: 28061473 DOI: 10.18632/oncotarget.14388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
431 Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF. Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv 2017;1:1324-34. [PMID: 29296775 DOI: 10.1182/bloodadvances.2017007260] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
432 Scheich S, Sebastian M. Immuncheckpointinhibitoren. Onkologe 2017;23:575-584. [DOI: 10.1007/s00761-017-0226-6] [Reference Citation Analysis]
433 Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Mol Oncol 2017;11:824-46. [PMID: 28614624 DOI: 10.1002/1878-0261.12093] [Cited by in Crossref: 211] [Cited by in F6Publishing: 223] [Article Influence: 35.2] [Reference Citation Analysis]
434 Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017;123:3763-71. [PMID: 28640385 DOI: 10.1002/cncr.30818] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
435 Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jagal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer 2017;5:49. [PMID: 28642818 DOI: 10.1186/s40425-017-0252-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
436 Biasoli I, Spector N. New agents in relapsed/refractory Hodgkin's lymphoma. Rev Bras Hematol Hemoter 2017;39:193-6. [PMID: 28830595 DOI: 10.1016/j.bjhh.2017.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
437 Braun DA, Wu CJ. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J 2017;23:115-24. [PMID: 28410299 DOI: 10.1097/PPO.0000000000000257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
438 Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, Ando K, Terui Y, Higuchi Y, Onishi Y, Abe Y, Kobayashi T, Shirasugi Y, Tobinai K. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci 2017;108:1007-12. [PMID: 28267244 DOI: 10.1111/cas.13230] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
439 Kim BJ, Jang HJ, Kim HS, Kim JH. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer 2017;8:1460-5. [PMID: 28638461 DOI: 10.7150/jca.18470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
440 Curran EK, Godfrey J, Kline J. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol 2017;38:513-25. [PMID: 28511816 DOI: 10.1016/j.it.2017.04.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 11.3] [Reference Citation Analysis]
441 Bond DA, Alinari L. Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. J Blood Med 2017;8:41-54. [PMID: 28546779 DOI: 10.2147/JBM.S117452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
442 Karantanos T, Politikos I, Boussiotis VA. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood Lymphat Cancer 2017;7:37-52. [PMID: 28701859 DOI: 10.2147/BLCTT.S105458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
443 Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 2017;10:103. [PMID: 28482851 DOI: 10.1186/s13045-017-0474-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 14.5] [Reference Citation Analysis]
444 Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017;130:221-8. [PMID: 28468799 DOI: 10.1182/blood-2017-01-761346] [Cited by in Crossref: 174] [Cited by in F6Publishing: 186] [Article Influence: 29.0] [Reference Citation Analysis]
445 Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 2017;35:2125-32. [PMID: 28441111 DOI: 10.1200/JCO.2016.72.1316] [Cited by in Crossref: 659] [Cited by in F6Publishing: 700] [Article Influence: 109.8] [Reference Citation Analysis]
446 Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol 2017;10:94. [PMID: 28434396 DOI: 10.1186/s13045-017-0453-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
447 Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist 2017;22:585-91. [PMID: 28438889 DOI: 10.1634/theoncologist.2017-0004] [Cited by in Crossref: 94] [Cited by in F6Publishing: 103] [Article Influence: 15.7] [Reference Citation Analysis]
448 Yamasaki M, Saito N, Hada Y, Miyamoto S, Okanobu H, Ikeda N, Daido W, Ishiyama S, Deguchi N, Taniwaki M, Ohashi N. Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. Case Rep Oncol 2017;10:361-7. [PMID: 28559820 DOI: 10.1159/000470830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
449 Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig 2017;4:32. [PMID: 28529947 DOI: 10.21037/sci.2017.03.04] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
450 El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, Jisr T, Mougharbel A, Ibrahim A, Bazarbachi A. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant 2017;52:1074-7. [PMID: 28394366 DOI: 10.1038/bmt.2017.69] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
451 Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017;129:3071-3. [PMID: 28356247 DOI: 10.1182/blood-2017-01-764209] [Cited by in Crossref: 259] [Cited by in F6Publishing: 277] [Article Influence: 43.2] [Reference Citation Analysis]
452 Gay ND, Okada CY, Chen AI, Scott EC. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. Ther Adv Hematol 2017;8:175-80. [PMID: 28473905 DOI: 10.1177/2040620717695723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
453 Covut F, Pinto R, Cooper BW, Tomlinson B, Metheny L, Malek E, Lazarus HM, de Lima M, Caimi PF. Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2017;52:1054-6. [PMID: 28346414 DOI: 10.1038/bmt.2017.44] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
454 Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep 2017;7:44173. [PMID: 28272463 DOI: 10.1038/srep44173] [Cited by in Crossref: 45] [Cited by in F6Publishing: 54] [Article Influence: 7.5] [Reference Citation Analysis]
455 Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J Radiol 2017; 9(2): 27-33 [PMID: 28298962 DOI: 10.4329/wjr.v9.i2.27] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
456 Skoetz N, Goldkuhle M, Gartlehner G, Monsef I, Dahm P, Glossmann J, Engert A, von Tresckow B. Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer). Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
457 Oncale MB, Maymani H, Nastoupil LJ. Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. Blood Lymphat Cancer 2017;7:1-7. [PMID: 31360081 DOI: 10.2147/BLCTT.S110665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
458 Galanina N, Kline J, Bishop MR. Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol 2017;8:81-90. [PMID: 28203344 DOI: 10.1177/2040620716673787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
459 Onizuka M, Kojima M, Matsui K, Machida S, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Nakamura N, Ando K. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol 2017;106:141-5. [PMID: 28097534 DOI: 10.1007/s12185-017-2181-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
460 Scholz C, Eucker J. Hodgkin-Lymphom. Facharztwissen Hämatologie Onkologie 2017. [DOI: 10.1016/b978-3-437-21214-7.00011-0] [Reference Citation Analysis]
461 Zain J, Kwak LW. Overview of lymphoma. Management of Lymphomas: A Case-Based Approach 2017. [DOI: 10.1007/978-3-319-26827-9_1] [Reference Citation Analysis]
462 Phillips T, Devata S, Wilcox RA. Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer 2016;4:95. [PMID: 28031823 DOI: 10.1186/s40425-016-0201-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
463 Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017;41:100-10. [PMID: 28189263 DOI: 10.1016/j.currproblcancer.2016.12.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 9.6] [Reference Citation Analysis]
464 Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res 2016;4:910-6. [PMID: 27737878 DOI: 10.1158/2326-6066.CIR-16-0201] [Cited by in Crossref: 113] [Cited by in F6Publishing: 122] [Article Influence: 16.1] [Reference Citation Analysis]
465 Gisselbrecht C. Is nivolumab an option for Hodgkin's lymphoma? The Lancet Oncology 2016;17:1183-1184. [DOI: 10.1016/s1470-2045(16)30220-0] [Reference Citation Analysis]